Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Last updated: October 5, 2020
Sponsor: Bausch & Lomb Incorporated
Overall Status: Completed

Phase

3

Condition

Eye Disorders/infections

Allergy

Allergy (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00770133
572
  • Ages > 6
  • All Genders

Study Summary

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Positive history of ocular allergies and positive skin test reaction to cat hair, catdander, grasses, ragweed, and/or trees within the past 24 months.
  • Calculated best-corrected visual acuity of 0.7 logMAR or better in each eye asmeasured using the ETDRS chart.
  • Positive bilateral conjunctival allergen challenge(CAC) reaction within 10 minutes ofinstillation of the last titration of allergen at visit 1.
  • Positive bilateral CAC reaction for at least 2 out of 3 time points at visit 2.

Exclusion

Exclusion Criteria:

  • Known contraindications or sensitivities to the study medication or its components.
  • Any ocular condition that, in the opinion of the investigator, could affect thesubjects safety or trial parameters.
  • Use of disallowed medications during the period indicated prior to study enrollment orduring the study.

Study Design

Total Participants: 141
Study Start date:
February 01, 2010
Estimated Completion Date:
June 30, 2010

Connect with a study center

  • Ophthalmic Research Consultants, Inc.

    North Andover, Massachusetts 01845
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.